Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 09
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Ovid Therapeutics Inc
OVID
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$2.34
-0.02
-0.85%
Dern. MÀJ: Oct 8, 6:31 PM
$2.33
-0.03
-1.27%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Ovid Therapeutics Financials
Ovid Therapeutics (OVID) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share
Benzinga Newsdesk
PRO
Ovid Therapeutics Q1 EPS $(0.12) Misses $(0.11) Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 14.29 percent increase over losses of $(0.14) per share
Benzinga Newsdesk
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally
Ovid Therapeutics shares climb after positive epilepsy data, new trial launch, and $60 million funding boost extending runway into 2028.
Vandana Singh
Earnings Scheduled For March 18, 2026
Benzinga Insights
PRO
Ovid Therapeutics Q4 EPS $0.06 Beats $(0.11) Estimate, Sales $718.000K Beat $13.333K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.11) by 152.63 percent. This is a 146.15 percent increase over losses of $(0.13) per share
Benzinga Newsdesk
PRO
Ovid Therapeutics Q3 EPS $(0.17) Misses $(0.15) Estimate, Sales $132.000K Beat $131.429K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 15.65 percent. This is a 15 percent increase over losses of $(0.20) per share from
Benzinga Newsdesk
